News & Views
Morphosys and Integrated Biotherapeutics Provide Update Regarding Usamriid Biodefense Project
Jul 15 2008
Staphylococcal enterotoxins are involved in a variety of human pathologies ranging from hospital and community-acquired infections, sepsis, toxic shock syndrome, to atopic dermatitis. Staphylococcal enterotoxin B is also considered as a potential agent of bioterrorism. Currently no vaccines or immunotherapeutics are available against staphylococcal toxins or S. aureus infections. The research collaboration between IBT and AbD Serotec follows a novel paradigm in the fight against these pathogens by targeting toxins released by bacteria which can distract the immune system and cause massive and even fatal damage.
"This grant allows us to continue a very promising project initiated by USAMRIID and AbD Serotec", said Dr. M. Javad Aman, President and CSO of IBT,IBT is extremely pleased to have access to AbD`s unique technology for developing antibodies with therapeutic potential in this important medical area.
Today`s news marks yet another promising development of a pre-existing customer relationship of AbD Serotec, comments Dr. Achim Knappik, Head of R&D at AbD Serotec. We look forward to work with Integrated BioTherapeutics on this promising project in the field of infectious diseases which is an interesting research market for AbD Serotec.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark